Lymphoma
Conditions
Brief summary
The lymph nodes or masses,positron emission tomography/computed tomography (PET/CT) standardized uptake values(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D\*, f values and MRI volumes of lymphoma patients were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. Long-term therapeutic effect indexes obtained in follow-up visits of patients such as Overall Survival(OS), Progression Free Survival (PFS) etc. were used to evaluate the diagnostic sensitivity and differences of MRI and PET/CT. The research could provide a new method of nonionizing radiation iconography for physicians to give appropriate treatments and predict prognosis.
Interventions
DEVICEmagnetic resonance imaging
MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
RADIATIONfludeoxyglucose F 18
Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
Sponsors
Guangxi Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by a reference pathologist. * Patients who gave written informed consent were referred for DWI-MRI and 18F-FDG-PET/CT. * Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).
Exclusion criteria
* Pregnancy, general contraindications to MRI, and therapeutic interventions between DWI-MRI and 18F-FDG-PET/CT were used.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-FDG uptake in lymphomas with PET/CT | Within 30 days prior to start of chemotherapy | Different 18F-FDG uptake values in lymphoma tissue (e.g. SUVmax, SUVmean, binding potential) will be measured and correlated with immunohistochemically determined somatostatin receptor status, lymphoma aggressiveness and tissue biomarkers |
| Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis | Within 30 days prior to start of chemotherapy | Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT at diagnosis. |
| Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations | 2 weeks after the 4th cycle of chemotherapy | Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT after completion of chemotherapy for treatment response assessment |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival | 12 months |
| Progression Free Survival | 6 months |
Countries
China
Contacts
Primary ContactChengcheng Liao, MD
Outcome results
None listed